Cargando…

Kidney dosimetry in 777 patients during (177)Lu-DOTATATE therapy: aspects on extrapolations and measurement time points

PURPOSE: Fractionated peptide receptor radionuclide therapy (PRRT) with (177)Lu-DOTATATE is increasingly applied as an effective treatment for patients with disseminated neuroendocrine tumors. In parallel to dose planning before external beam radiation therapy, dosimetry is also needed to optimize P...

Descripción completa

Detalles Bibliográficos
Autores principales: Sandström, Mattias, Freedman, Nanette, Fröss-Baron, Katarzyna, Kahn, Tanweera, Sundin, Anders
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7726073/
https://www.ncbi.nlm.nih.gov/pubmed/33296054
http://dx.doi.org/10.1186/s40658-020-00339-2
_version_ 1783620809716137984
author Sandström, Mattias
Freedman, Nanette
Fröss-Baron, Katarzyna
Kahn, Tanweera
Sundin, Anders
author_facet Sandström, Mattias
Freedman, Nanette
Fröss-Baron, Katarzyna
Kahn, Tanweera
Sundin, Anders
author_sort Sandström, Mattias
collection PubMed
description PURPOSE: Fractionated peptide receptor radionuclide therapy (PRRT) with (177)Lu-DOTATATE is increasingly applied as an effective treatment for patients with disseminated neuroendocrine tumors. In parallel to dose planning before external beam radiation therapy, dosimetry is also needed to optimize PRRT to the individual patient. Accordingly, absorbed doses to organs at risk need to be calculated during PRRT, based on serial measurements of radioactivity distribution utilizing SPECT/CT. The dosimetry should be based on as few measurements as possible, while still retaining reliable results. The main aim of the present work was to calculate the fractional contribution of the extrapolations of the curve fits for the absorbed dose calculations to the kidneys. The secondary aim was to study agreement between absorbed dose (AD) and the effective half-life (t(eff)) for the kidneys, estimated by means of measurements at one or two time points, in comparison to our current method employing three time points. METHODS: In 777 patients with disseminated neuroendocrine tumors undergoing PRRT, SPECT/CT over the abdomen was acquired at 1, 4, and 7 days after (177)Lu-DOTATATE infusion. The absorbed dose to the kidneys was calculated from SPECT/CT radioactivity distribution data, and the t(eff) and fractional contributions of the extrapolations were estimated, utilizing data from one, two, and three time points, respectively. RESULTS: The fractional contributions from extrapolations before day 1 measurement and after day 7 measurement were approximately 26% and 11%, respectively. The mean differences in absorbed dose, based on one, two, and three time points were small, but with high method dependence for individual patients. The differences in estimated t(eff) were small when it was based on measurements at days 1 and 7, but high for days 1 and 4 time points. CONCLUSION: When assessing simplifications of methods for calculation of the absorbed dose to the kidneys, it was of the uttermost importance to incorporate the fractional contribution for the extrapolations included in the reference method. Measurements at an early and a late time point were found most important. An intermediate measurement contributes with an idea of the goodness of the fit.
format Online
Article
Text
id pubmed-7726073
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-77260732020-12-17 Kidney dosimetry in 777 patients during (177)Lu-DOTATATE therapy: aspects on extrapolations and measurement time points Sandström, Mattias Freedman, Nanette Fröss-Baron, Katarzyna Kahn, Tanweera Sundin, Anders EJNMMI Phys Original Research PURPOSE: Fractionated peptide receptor radionuclide therapy (PRRT) with (177)Lu-DOTATATE is increasingly applied as an effective treatment for patients with disseminated neuroendocrine tumors. In parallel to dose planning before external beam radiation therapy, dosimetry is also needed to optimize PRRT to the individual patient. Accordingly, absorbed doses to organs at risk need to be calculated during PRRT, based on serial measurements of radioactivity distribution utilizing SPECT/CT. The dosimetry should be based on as few measurements as possible, while still retaining reliable results. The main aim of the present work was to calculate the fractional contribution of the extrapolations of the curve fits for the absorbed dose calculations to the kidneys. The secondary aim was to study agreement between absorbed dose (AD) and the effective half-life (t(eff)) for the kidneys, estimated by means of measurements at one or two time points, in comparison to our current method employing three time points. METHODS: In 777 patients with disseminated neuroendocrine tumors undergoing PRRT, SPECT/CT over the abdomen was acquired at 1, 4, and 7 days after (177)Lu-DOTATATE infusion. The absorbed dose to the kidneys was calculated from SPECT/CT radioactivity distribution data, and the t(eff) and fractional contributions of the extrapolations were estimated, utilizing data from one, two, and three time points, respectively. RESULTS: The fractional contributions from extrapolations before day 1 measurement and after day 7 measurement were approximately 26% and 11%, respectively. The mean differences in absorbed dose, based on one, two, and three time points were small, but with high method dependence for individual patients. The differences in estimated t(eff) were small when it was based on measurements at days 1 and 7, but high for days 1 and 4 time points. CONCLUSION: When assessing simplifications of methods for calculation of the absorbed dose to the kidneys, it was of the uttermost importance to incorporate the fractional contribution for the extrapolations included in the reference method. Measurements at an early and a late time point were found most important. An intermediate measurement contributes with an idea of the goodness of the fit. Springer International Publishing 2020-12-09 /pmc/articles/PMC7726073/ /pubmed/33296054 http://dx.doi.org/10.1186/s40658-020-00339-2 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Original Research
Sandström, Mattias
Freedman, Nanette
Fröss-Baron, Katarzyna
Kahn, Tanweera
Sundin, Anders
Kidney dosimetry in 777 patients during (177)Lu-DOTATATE therapy: aspects on extrapolations and measurement time points
title Kidney dosimetry in 777 patients during (177)Lu-DOTATATE therapy: aspects on extrapolations and measurement time points
title_full Kidney dosimetry in 777 patients during (177)Lu-DOTATATE therapy: aspects on extrapolations and measurement time points
title_fullStr Kidney dosimetry in 777 patients during (177)Lu-DOTATATE therapy: aspects on extrapolations and measurement time points
title_full_unstemmed Kidney dosimetry in 777 patients during (177)Lu-DOTATATE therapy: aspects on extrapolations and measurement time points
title_short Kidney dosimetry in 777 patients during (177)Lu-DOTATATE therapy: aspects on extrapolations and measurement time points
title_sort kidney dosimetry in 777 patients during (177)lu-dotatate therapy: aspects on extrapolations and measurement time points
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7726073/
https://www.ncbi.nlm.nih.gov/pubmed/33296054
http://dx.doi.org/10.1186/s40658-020-00339-2
work_keys_str_mv AT sandstrommattias kidneydosimetryin777patientsduring177ludotatatetherapyaspectsonextrapolationsandmeasurementtimepoints
AT freedmannanette kidneydosimetryin777patientsduring177ludotatatetherapyaspectsonextrapolationsandmeasurementtimepoints
AT frossbaronkatarzyna kidneydosimetryin777patientsduring177ludotatatetherapyaspectsonextrapolationsandmeasurementtimepoints
AT kahntanweera kidneydosimetryin777patientsduring177ludotatatetherapyaspectsonextrapolationsandmeasurementtimepoints
AT sundinanders kidneydosimetryin777patientsduring177ludotatatetherapyaspectsonextrapolationsandmeasurementtimepoints